Clinical Trial

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19. Cycle length will be 28 days. Patients will be monitored closely for toxicity and undergo imaging to evaluate efficacy once every 2 cycles.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2017-03-28; most recent amendment 2025-07-31.
Status change: Suspended → Recruiting 2020-06-15
Status change: Recruiting → Suspended 2020-04-29
Status change: Not Yet Recruiting → Recruiting 2017-05-23
Trial Details
NCT Number NCT03099356
Lead Sponsor University of Michigan Rogel Cancer Center
Conditions Metastatic Thyroid Cancer
Enrollment 22 participants
Start Date 2017-04-27
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-31